Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

McGill University

$150,000.00

Impact of PGC-1 on the development of therapeutic resistance in breast cancer

EF 2014-15

Résumé
Every year, new therapeutic drugs are released for clinical trials to provide a better outcome for patients afflicted with cancer. However, the efficiency of therapy is greatly limited by the speed at which tumors develop a resistance to the drug. Currently, the best solution is to provide patients either with a second drug after their cancer develops resistance to the first, or to combine drugs to attack several targets at once in the hope that at least one drug will work. Cancer cells behave very differently from normal cells; they show a significant metabolic shift - cancer cells will prefer to rapidly generate energy from glucose rather than generate more balanced, efficient, and renewable energy using mitochondria, which are not only the powerhouse of the cell but also an important source for building blocks that serve the rest of the cell. Similarly, therapy-resistant cancer cells are different from therapy-sensitive cancer cells; we have evidence that resistant cells adapt their metabolism in order to survive. To study this phenomenon, we have developed methods to look at the metabolism of cancer cells at the molecular level using the state-of-the-art Metabolomics Core Facility of McGill's Goodman Cancer Research Centre. By following the flow of labelled tracers through these metabolic pathways, we will investigate differences in the metabolic flux of therapy-resistant and therapy-sensitive breast cancer cells, while observing the expression of genes and enzymes responsible for the regulation of metabolism. With these tools, we aim to uncover metabolic vulnerabilities of therapy-resistant cancer cells in order to move forward potential therapy that could ultimately benefit cancer patients
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
318178
Name
McGuirk Shawn
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Impact of PGC-1 on the development of therapeutic resistance in breast cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Apoptosis; Breast Cancer; Chemoresistance; Dna Damage; Genomics; Metabolism; Metabolomics; Mitochondria; Therapeutic Resistance
Abstract
Every year, new therapeutic drugs are released for clinical trials to provide a better outcome for patients afflicted with cancer. However, the efficiency of therapy is greatly limited by the speed at which tumors develop a resistance to the drug. Currently, the best solution is to provide patients either with a second drug after their cancer develops resistance to the first, or to combine drugs to attack several targets at once in the hope that at least one drug will work. Cancer cells behave very differently from normal cells; they show a significant metabolic shift - cancer cells will prefer to rapidly generate energy from glucose rather than generate more balanced, efficient, and renewable energy using mitochondria, which are not only the powerhouse of the cell but also an important source for building blocks that serve the rest of the cell. Similarly, therapy-resistant cancer cells are different from therapy-sensitive cancer cells; we have evidence that resistant cells adapt their metabolism in order to survive. To study this phenomenon, we have developed methods to look at the metabolism of cancer cells at the molecular level using the state-of-the-art Metabolomics Core Facility of McGill's Goodman Cancer Research Centre. By following the flow of labelled tracers through these metabolic pathways, we will investigate differences in the metabolic flux of therapy-resistant and therapy-sensitive breast cancer cells, while observing the expression of genes and enzymes responsible for the regulation of metabolism. With these tools, we aim to uncover metabolic vulnerabilities of therapy-resistant cancer cells in order to move forward potential therapy that could ultimately benefit cancer patients
Competitiondate
201411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
McGuirk, Shawn
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~